Related Experiment Videos
[Experimental and clinical studies on subrenal capsule assay for predicting individual tumor chemosensitivity]
Abstract:
Subrenal capsule assay (SRC assay) was investigated to evaluate the usefulness as an in vivo chemosensitivity test of anticancer agents. The pathological study on the growth of the implanted tumor and host response indicated that the assay had to be done by four-day assay. The analysis of the isotope incorporation into the implanted tumor supported this results. As determination of tumor sensitivity by the microscopic measurement showed the large standard deviation, the DNA and protein content was determined for the evaluation of sensitivity by percent inhibition of the DNA/protein content (%DNA/protein). Ninety five fresh tumor specimens were examined and evaluated by relative variation of the calculated tumor weight (delta TW/TW0), while 64 specimens by %DNA/protein. The evaluability rates using delta TW/TW0 and %DNA/protein were 84.2% and 87.5%, respectively. All over predictive accuracy between the clinical responses and the results of the assay evaluated by delta TW/TW0 was 78.6%, while 81.8% was obtained by %DNA/protein. From these results, the potential utility of SRC assay examined on 4 day for determining chemosensitivity by %DNA/protein seems to be beneficial for clinical use.
Insights
The subrenal capsule (SRC) assay is a valuable in vivo chemosensitivity test for anticancer drugs. Evaluating sensitivity using DNA/protein content over four days offers high predictive accuracy for clinical use.
Area of Science:
- Oncology
- Pharmacology
- Experimental Pathology
Context:
- The subrenal capsule (SRC) assay is an established method for in vivo drug testing.
- Accurate chemosensitivity testing is crucial for effective cancer treatment selection.
- Previous methods for SRC assay evaluation had limitations in precision and predictive value.
Purpose:
- To investigate the utility of the SRC assay as a predictive in vivo chemosensitivity test for anticancer agents.
- To determine the optimal duration and measurement method for the SRC assay.
- To assess the evaluability and predictive accuracy of the SRC assay compared to clinical responses.
Summary:
- A four-day SRC assay protocol was developed and validated using pathological and isotope incorporation analyses.
- Tumor sensitivity was evaluated by measuring DNA/protein content (%DNA/protein), which proved more reliable than microscopic tumor weight measurements.
- The %DNA/protein method demonstrated high evaluability rates (87.5%) and predictive accuracy (81.8%) for clinical responses.
Impact:
- The optimized four-day SRC assay using %DNA/protein content shows significant potential for clinical application in personalized cancer therapy.
- This method can aid clinicians in selecting the most effective anticancer agents for individual patients.
- Improved chemosensitivity testing through the SRC assay could lead to better treatment outcomes and reduced drug resistance.